8224 results for "canc*"

in 10.76 milliseconds.

• Arcagen - Extra-pulmonary neuroendocrine tumour or cancer grade 3 (NET / NEC G3) domain

  Arcagen is an EORTC/SPECTA pan-European project that aims to recruit 1000 rare cancer patients from different tumour domains of EURACAN. This study collected samples from advanced or metastatic rare cancer from patients older than 12, and analysed them using Foundation Medicine next-generation sequencing (NGS) panels (FoundationOne CDx for FFPE samples or FoundationOne Liquid CDx for blood samples). Here were are submitting the dataset that contains NGS files from patients with extra-pulmonary neuroendocrine tumour or cancer grade 3 (NET / NEC G3) (n=85).

  Study EGAS50000000644

• Djerroudi et al., E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular carcinoma

  Invasive lobular breast carcinoma (ILC) shows specific stromal features, T lymphocyte infiltration (TIL) being associated with poor prognosis. Here, we reveal the involved mechanism by performing single cell RNA sequencing, combined immunohistochemistry, deconvolution of bulk RNA sequencing from large retrospective ILC series, and functional assays using primary cells. We show that ILC accumulate FAP+ inflammatory cancer-associated fibroblasts (iCAF) through a previously undescribed mechanism mediated by E-cadherin/CDH1 on CAF plasticity. Indeed, CDH1 inactivation in ILC cancer cells prevents differentiation of iCAF into myofibroblastic CAF (myCAF), leading to iCAF accumulation. In turn, iCAF increase TIL infiltration and shape their spatial organization in ILC. Subsequently, CDH1-inactivated ILC cancer cells promote immune escape by lack of retention and activation of ITGAE-expressing resident memory CD8+ T lymphocytes (TRM). Hence, our study uncovers reciprocal interactions between CDH1-inactivated cancer cells, iCAF and CD8+ TRM, revealing why and how TILs have a poor prognosis in ILC patients, a mechanism extrapolated to other CDH1-mutated cancer types.

  Study EGAS50000000761

• Arcagen - CNS domain

  Arcagen is an EORTC/SPECTA pan-European project that aims to recruit 1000 rare cancer patients from different tumour domains of EURACAN. This study collected samples from advanced or metastatic rare cancer from patients older than 12, and analysed them using Foundation Medicine next-generation sequencing (NGS) panels (FoundationOne CDx for FFPE samples or FoundationOne Liquid CDx for blood samples). Here we are submitting the dataset from patients with rare tumor from the central nervous system (n=61).

  Study EGAS50000001002

• Tumor Profiler Ovarian Study

  The Tumor Profiler Study is an observational trial combining a prospective diagnostic approach to assess the relevance of in-depth tumor profiling to support clinical decision-making with an exploratory approach to improve the biological understanding of the disease. Technologies used are digital pathology, targeted NGS, single-cell RNA, single-cell DNA, bulk RNA, bulk proteotyping, single-cell CyTOF, imaging mass cytometry, pharmacoscopy, 4i Drug Response Profiling, and cell-free DNA. These technologies were applied to 240 tumor samples collected over 3 years across three cancer indications: metastatic melanoma, metastatic epithelial ovarian cancer, and acute myeloid leukemia (AML). Here, we publish the scRNA and scDNA data of the ovarian cancer cohort.

  Study EGAS50000000885

• Precision tumor-on-chip for personalized assessment of drug efficacy and immune cell delivery

  Tumor heterogeneity and drug resistance limit the efficacy of cancer therapies and highlight the need for patient-specific preclinical models. We developed a microfluidic tumor-on-chip (TOC) platform that integrates patient-derived organoids with a functional endothelial barrier to recreate drug and immune cell transport from the vasculature into tumor tissue. This system enables evaluation of therapeutic efficacy, toxicity, and immune cell migration under physiologically relevant conditions. In a clinical pancreatic cancer case, the TOC model predicted treatment resistance and uncovered gene expression shifts and pathway rewiring at single-cell resolution. By simulating vascular drug transport, the platform provides a scalable and clinically relevant tool for studying treatment response mechanisms and tailoring cancer treatments.

  Study EGAS50000001605

• Lung Cancer Research Program Genomics Data Access Committee, University of California, Los Angeles

  The committee is responsible for reviewing and approving requests for access to genomic data generated by the Lung Cancer Research Program at the David Geffen School of Medicine at UCLA and ensuring compliance with applicable data-sharing policies, institutional requirements, and relevant regulations.

  Dac EGAC50000001154

• Combination of a CCL21-gene modified dendritic cell vaccine and pembrolizumab induces immune responses in non-small cell lung cancer.

  In a phase I study of advanced NSCLC, intratumoral CCL21-DC vaccination combined with pembrolizumab was safe and resulted in stable disease in 36.8% of patients. Analysis of paired pre- and post-treatment tumor biopsy WES data, together with immune profiling of tumor biopsies and peripheral blood, revealed that disease stability was associated with increased T cell receptor diversity, enhanced CD4+ T cell infiltration, and expansion of novel CD4+ memory T cell clones. These findings suggest that CCL21-DC vaccination can stimulate antitumor immunity; however, its efficacy may be limited by insufficient tumor-specific T cell responses and persistent immunosuppressive signaling within the tumor microenvironment.

  Study EGAS50000002127

• Phenomic and multiomic characterisation of microsatellite-stable colorectal cancer reveals novel biology and targets of vulnerability (COLOSSUS project): snRNASeq cohort

  This dataset contains single-nuclei RNA-sequencing (n = 18) samples. Primary tumour samples were obtained from a) colorectal cancer patients with stage 2 / 3 disease and b) colorectal cancer patients who developed metastatic colorectal cancer (stage 4), for whom tissue from the primary tumour was available.

  Study EGAS50000002087

• Phenomic and multiomic characterisation of microsatellite-stable colorectal cancer reveals novel biology and targets of vulnerability (COLOSSUS project): Stage (St) 2/3 CRC cohort

  This dataset contains bulk RNA sequencing (n = 184), low-coverage whole-genome sequencing (n = 182) and whole-exome sequencing (n = 88) data. Primary tumour samples were obtained from colorectal cancer patients with stage 2 / 3 disease.

  Study EGAS50000002088

• Phenomic and multiomic characterisation of microsatellite-stable colorectal cancer reveals novel biology and targets of vulnerability (COLOSSUS project): metastatic (m)CRC cohort

  This dataset contains bulk RNA sequencing samples (n = 111) and low-coverage whole-genome sequencing (n = 113). Primary tumour samples were retrospectively obtained from colorectal cancer patients who developed metastatic colorectal cancer (stage 4), for whom tissue from the primary tumour was available.

  Study EGAS50000002086